Online inquiry

IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6757MR)

This product GTTS-WQ6757MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TACSTD2 gene. The antibody can be applied in Non Small Cell Lung Cancer (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002353.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4070
UniProt ID P09758
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6757MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6656MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ12117MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ4006MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ13710MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ6468MR IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P-59
GTTS-WQ6281MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ13432MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ4953MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA c13C6-FR1-N
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW